Prevalence and Impact of a Pathogenic CYP27A1 Variant on the Phenotypes Among Patients with Monogenic Heterozygous Familial Hypercholesterolemia
Abstract
OBJECTIVE: Cerebrotendinous xanthomatosis (CTX) is a rare inherited metabolic disorder caused by pathogenic variants of cytochrome P450 family 27 subfamily A member 1 (CYP27A1). It remains unclear whether such variants modify the clinical manifestations of familial hypercholesterolemia (FH) caused by defects in the low-density lipoprotein (LDL) receptor or other related genes. We aimed to clarify the impact of the pathogenic variants of CYP27A1 on the clinical phenotypes of patients with FH. METHODS: We analyzed clinical data from 644 patients with a clinical diagnosis of monogenic FH who underwent genotyping for CYP27A1 and phenotypic assessment, including the serum sterol levels. Multivariate linear regression analyses, adjusted for age and sex, were conducted to assess the impact of pathogenic CYP27A1 variants on the serum cholestanol levels. RESULTS: Among these individuals, 22 (3.4%) carried pathogenic CYP27A1 variants. Patients harboring a pathogenic variant showed significantly higher median cholestanol concentrations than non-carriers (3.7 vs. 2.3 μg/mL, p ＜0.001). A single pathogenic CYP27A1 variant was associated with an increase in serum cholestanol of 2.3 μg/mL (95% confidence interval: 1.4-3.2 μg/mL, p ＜0.001) and an Achilles tendon thickness of 0.4 mm (95% confidence interval: 0.1-0.7 mm, p = 0.02). Furthermore, carriers exhibited significantly greater Achilles tendon thickness than non-carriers (9.6 vs. 8.9 mm, p ＜0.001). CONCLUSIONS: We identified a substantial number of patients with pathogenic CYP27A1 variants among the patients with monogenic FH, which influenced their Achilles tendon thickness and serum cholestanol levels.
Related
- Effect of rosuvastatin and ezetimibe therapy on LDL-cholesterol reduction and non-invasive arterial injury markers in children with heterozygous familial hypercholesterolemia: a prospective, open-label, randomized study
- A case of renal hypouricemia type 1 associated with compound heterozygous URAT1/SLC22A12 variants A209V and F379L: clinical evidence for their pathogenic significance
- Double heterozygous pathogenic germline APC and MSH2 variants in a 16-year-old female diagnosed with colorectal cancer
- Plasma Lipidomic Phenotype Associated with Pathogenic LDLR Variants in Familial Hypercholesterolemia
- Age-stratified prevalence and associated risk factors of hypertension, diabetes and hypercholesterolemia in Nepal: Insights from the STEPS survey 2019
BibTeX
@article{tada2026prevalence,
title = {{Prevalence and Impact of a Pathogenic CYP27A1 Variant on the Phenotypes Among Patients with Monogenic Heterozygous Familial Hypercholesterolemia}},
author = {Hayato Tada and Atsushi Furukawa and Masayuki Takamura},
journal = {Internal Medicine},
year = {2026},
month = sep,
doi = {10.2169/internalmedicine.8090-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8090-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Prevalence and Impact of a Pathogenic CYP27A1 Variant on the Phenotypes Among Patients with Monogenic Heterozygous Familial Hypercholesterolemia
AU - Hayato Tada
AU - Atsushi Furukawa
AU - Masayuki Takamura
PY - 2026
DA - 2026/09/22
JO - Internal Medicine
DO - 10.2169/internalmedicine.8090-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8090-26/_article
AB - OBJECTIVE: Cerebrotendinous xanthomatosis (CTX) is a rare inherited metabolic disorder caused by pathogenic variants of cytochrome P450 family 27 subfamily A member 1 (CYP27A1). It remains unclear whether such variants modify the clinical manifestations of familial hypercholesterolemia (FH) caused by defects in the low-density lipoprotein (LDL) receptor or other related genes. We aimed to clarify the impact of the pathogenic variants of CYP27A1 on the clinical phenotypes of patients with FH. METHODS: We analyzed clinical data from 644 patients with a clinical diagnosis of monogenic FH who underwent genotyping for CYP27A1 and phenotypic assessment, including the serum sterol levels. Multivariate linear regression analyses, adjusted for age and sex, were conducted to assess the impact of pathogenic CYP27A1 variants on the serum cholestanol levels. RESULTS: Among these individuals, 22 (3.4%) carried pathogenic CYP27A1 variants. Patients harboring a pathogenic variant showed significantly higher median cholestanol concentrations than non-carriers (3.7 vs. 2.3 μg/mL, p ＜0.001). A single pathogenic CYP27A1 variant was associated with an increase in serum cholestanol of 2.3 μg/mL (95% confidence interval: 1.4-3.2 μg/mL, p ＜0.001) and an Achilles tendon thickness of 0.4 mm (95% confidence interval: 0.1-0.7 mm, p = 0.02). Furthermore, carriers exhibited significantly greater Achilles tendon thickness than non-carriers (9.6 vs. 8.9 mm, p ＜0.001). CONCLUSIONS: We identified a substantial number of patients with pathogenic CYP27A1 variants among the patients with monogenic FH, which influenced their Achilles tendon thickness and serum cholestanol levels.
SN - 1349-7235
SN - 0918-2918
ER -